| Name | Title | Contact Details |
|---|
OncoNano Medicine is developing a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease.
Arranta Bio is delivering on its vision to build the best-in-class microbiome contract development and manufacturing organization (CDMO) through our merger with a 10-year veteran CDMO, Captozyme, and the establishment of a commercial-ready manufacturing facility. We provide manufacturing and development support for live biotherapeutic products (LBPs) targeting gut health and microbiome-related diseases by providing development and manufacturing services that bring effective treatments to the market and patients in need.
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company headquartered in Hershey, PA with lab facilities in Rockville, MD. ITI is developing next generation vaccines based on the patented Lysosomal Associated Membrane Protein, or LAMP, Technology. Our LAMP-Vax™ vaccine platform significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. LAMP emerged from $20 million of NIH-funded research conducted by distinguished scientist Dr. Tom August at the Johns Hopkins University School of Medicine. ITI has the exclusive worldwide license to the LAMP technology patent estate and is commercializing ground-breaking next generation LAMP DNA vaccines, beginning with allergy, cancer and infectious disease.
Lantern Pharma, Inc. is a clinical stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action, and also rescuing or revitalizing abandoned or failed cancer drugs using machine learning techniques, genomic data and precision oncology trials.
R2 Technology, Inc. is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.